Fulcrum Therapeutics Inc (NASDAQ: FULC) kicked off on Monday, up 8.37% from the previous trading day, before settling in for the closing price of $2.51. Over the past 52 weeks, FULC has traded in a range of $2.40-$10.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 549.31% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -650.00%. With a float of $47.85 million, this company’s outstanding shares have now reached $53.97 million.
In an organization with 45 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 77.83%, operating margin of -27.37%, and the pretax margin is -12.16%.
Fulcrum Therapeutics Inc (FULC) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Fulcrum Therapeutics Inc is 11.36%, while institutional ownership is 86.68%. The most recent insider transaction that took place on May 07 ’24, was worth 1,831. In this transaction Principal Accounting Officer of this company sold 236 shares at a rate of $7.76, taking the stock ownership to the 11,571 shares.
Fulcrum Therapeutics Inc (FULC) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -650.00% per share during the next fiscal year.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Trading Performance Indicators
Take a look at Fulcrum Therapeutics Inc’s (FULC) current performance indicators. Last quarter, stock had a quick ratio of 22.63. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.28 in one year’s time.
Technical Analysis of Fulcrum Therapeutics Inc (FULC)
Let’s dig in a bit further. During the last 5-days, its volume was 0.41 million. That was inferior than the volume of 0.45 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 19.98%. Additionally, its Average True Range was 0.23.
During the past 100 days, Fulcrum Therapeutics Inc’s (FULC) raw stochastic average was set at 14.03%, which indicates a significant decrease from 39.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.47% in the past 14 days, which was lower than the 70.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.37, while its 200-day Moving Average is $4.94. However, in the short run, Fulcrum Therapeutics Inc’s stock first resistance to watch stands at $2.87. Second resistance stands at $3.01. The third major resistance level sits at $3.29. If the price goes on to break the first support level at $2.45, it is likely to go to the next support level at $2.17. Assuming the price breaks the second support level, the third support level stands at $2.03.
Fulcrum Therapeutics Inc (NASDAQ: FULC) Key Stats
The company with the Market Capitalisation of 146.82 million has total of 53,979K Shares Outstanding. Its annual sales at the moment are 80,000 K in contrast with the sum of -9,730 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -21,700 K.
